Lagging biotech stock Epizyme (EPZM) suddenly came to life Monday, jumping more than 30% in the wake of positive weekend data on its lymphoma drug. On Saturday at the annual International Conference on Malignant Lymphoma, Epizyme said that nine out of 15 advanced non-Hodgkins lymphoma (NHL) patients in a phase one study responded to tazemetostat (EPZ-6438), a first-in-class drug called an EZH2 inhbitor. Five of nine patients with diffuse large
Facebook (FB) stock rose Monday as the world’s largest social network received a substantial price target boost from investment bank Piper Jaffray, based on the revenue potential of Facebook’s Oculus virtual reality system. The Oculus VR goggles are set to hit the consumer market early next year, at a price expected to be around $400. Piper Jaffray raised its price target on Facebook stock to 120 from 92 and maintained its overweight rating.
Online video behemoth YouTube is no longer the dominant content provider it once was. A new report out Monday says Facebook (FB) is poised to become a “plausible alternative” to Google’s (GOOGL) video arm. According to Ampere Analysis, Facebook is earning 73 cents per monthly active user (MAU) on videos versus the 28 cents per MAU that YouTube is earning. Ampere says that Facebook is “making a serious play for content owners” and the social